Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; hypromellose; povidone; hyetellose; purified talc; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - tablet, modified release - excipient ingredients: purified talc; hyetellose; lactose monohydrate; hypromellose; povidone; magnesium stearate; titanium dioxide; indigo carmine; sunset yellow fcf; erythrosine; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - tablet, modified release - excipient ingredients: povidone; hypromellose; magnesium stearate; hyetellose; purified talc; lactose monohydrate; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 200 mg - tablet, modified release - excipient ingredients: magnesium stearate; cetostearyl alcohol; hyetellose; purified talc; macrogol 400; titanium dioxide; hypromellose; brilliant blue fcf; quinoline yellow - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 15 mg - tablet, modified release - excipient ingredients: lactose; hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; hypromellose; brilliant blue fcf; indigo carmine; quinoline yellow; iron oxide yellow; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 5 mg - tablet, modified release - excipient ingredients: magnesium stearate; lactose; cetostearyl alcohol; purified talc; hyetellose; titanium dioxide; hypromellose; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose; povidone; pregelatinised maize starch; magnesium stearate; purified talc; titanium dioxide; brilliant blue fcf; hypromellose; macrogol 400 - treatment of chronic severe pain of cancer.

Malta - English - Medicines Authority

a. menarini industrie farmaceutiche riunite s.r.l. via sette santi 3, 50131, florence, italy - otilonium bromide - film-coated tablet - otilonium bromide 40 mg - drugs for functional gastrointestinal disorders

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

awal pharmacy - otilonium bromide - tablet - 40

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

lebasi pharmaceuticals (pty) ltd - tablet - not indicated - none